The transcriptional regulation of cardiomyocyte polyploidization and its relevance in cardiac regeneration
REACTIVA aims to promote heart regeneration by reactivating adult diploid cardiomyocytes through a newly identified regulatory network and inhibiting a specific transcription factor.
Projectdetails
Introduction
The mammalian heart is a non-regenerative organ due to the extremely limited ability of fully differentiated cardiomyocytes (CMs) to proliferate. While neonatal hearts still contain mostly diploid CMs and regenerate efficiently, physiological postnatal CM polyploidization/hypertrophy ensures the contractile capacity of the adult myocardium but represents a roadblock to cardiac regeneration.
Problem Statement
Due to this limitation, diseases that provoke CM loss, like acute ischemia, frequently lead to heart failure.
Project Overview
REACTIVA will establish a new strategy for heart regeneration based on the reactivation of a dormant endogenous mechanism, thereby achieving unprecedented advances in the field of cardiac regenerative biology.
Research Findings
In mice, the proportion of adult diploid CMs (ADCs) correlates with regenerative ability. However, efforts to identify a molecular signature for ADCs have been unsuccessful, which has precluded exploring their roles in heart regeneration.
Using an improved methodology for single-CM RNAseq, my group has identified a molecular signature of ADCs related to the fetal program and controlled by a single repressor transcription factor. This factor is specifically expressed in the polyploid CM population (PCM) and its inhibition in the postnatal mouse heart robustly increases ADC abundance and proliferative activity.
Hypothesis
Based on these findings, we propose that ADCs underlie a vestigial endogenous mechanism for adult mammalian heart renewal and that their stimulation will promote heart regeneration.
Objectives
REACTIVA will exploit our new findings on ADCs to:
- Fully characterize the ADC regulatory network, identifying factors to modulate it.
- Identify and trace ADCs in the adult heart, defining their niches and contribution to renew and expand the CM population during heart homeostasis, aging, and disease.
- Use the generated knowledge to induce ADC activation with the goal of promoting adult mammalian heart regeneration.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.500.000 |
Totale projectbegroting | € 2.500.000 |
Tijdlijn
Startdatum | 1-10-2024 |
Einddatum | 30-9-2029 |
Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (F.S.P.)penvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Harnessing Novel Micropeptides in Cardiomyocytes to promote Cardiac RegenerationNovel.CaRe aims to enhance cardiac regeneration post-myocardial infarction by using micropeptides to stimulate cardiomyocyte proliferation and maturation through innovative gene therapy approaches. | ERC Starting... | € 1.592.281 | 2024 | Details |
Programming the EPIcardium to CURE broken heartsEPICURE aims to decode human epicardial development and regeneration using pluripotent stem cell-derived epicardioids, enhancing insights for cardiac repair through advanced imaging and CRISPR techniques. | ERC Advanced... | € 2.499.999 | 2024 | Details |
Mechanisms and consequences of cell state transitions during heart regenerationThis project aims to uncover the coordinated cellular responses in zebrafish heart regeneration post-injury using single-cell genomics and computational methods to enhance understanding of organ repair mechanisms. | ERC Consolid... | € 2.000.000 | 2023 | Details |
Universal Cardiac Mesoangioblasts for treating DMD Dilated CardiomyopathyThe project aims to develop immune-privileged cardiac mesoangioblasts that can be converted to cardioblasts for targeted treatment of dilated cardiomyopathy, enhancing heart repair. | ERC Proof of... | € 150.000 | 2025 | Details |
Restoring anisotropy in living tissues 'in situ'This project aims to enhance cardiac tissue regeneration by restoring structural anisotropy using ultrasound, improving therapy outcomes through a multidisciplinary and technology-driven approach. | ERC Advanced... | € 3.056.887 | 2022 | Details |
Harnessing Novel Micropeptides in Cardiomyocytes to promote Cardiac Regeneration
Novel.CaRe aims to enhance cardiac regeneration post-myocardial infarction by using micropeptides to stimulate cardiomyocyte proliferation and maturation through innovative gene therapy approaches.
Programming the EPIcardium to CURE broken hearts
EPICURE aims to decode human epicardial development and regeneration using pluripotent stem cell-derived epicardioids, enhancing insights for cardiac repair through advanced imaging and CRISPR techniques.
Mechanisms and consequences of cell state transitions during heart regeneration
This project aims to uncover the coordinated cellular responses in zebrafish heart regeneration post-injury using single-cell genomics and computational methods to enhance understanding of organ repair mechanisms.
Universal Cardiac Mesoangioblasts for treating DMD Dilated Cardiomyopathy
The project aims to develop immune-privileged cardiac mesoangioblasts that can be converted to cardioblasts for targeted treatment of dilated cardiomyopathy, enhancing heart repair.
Restoring anisotropy in living tissues 'in situ'
This project aims to enhance cardiac tissue regeneration by restoring structural anisotropy using ultrasound, improving therapy outcomes through a multidisciplinary and technology-driven approach.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Cardiogenomics meets Artificial Intelligence: a step forward in arrhythmogenic cardiomyopathy diagnosis and treatmentThe project aims to integrate genomics, proteomics, and structural analyses to clarify genotype-phenotype relationships in arrhythmogenic cardiomyopathy, paving the way for novel therapies. | EIC Pathfinder | € 3.740.868 | 2023 | Details |
Comprehensive Analysis of RBM20-induced Dilated Cardiomyopathies using Omics Approaches and Repair InterventionsCARDIOREPAIR aims to identify and therapeutically target RBM20 mutations in dilated cardiomyopathy using high-throughput genomics and bioengineering to improve heart health outcomes. | EIC Pathfinder | € 4.349.410 | 2023 | Details |
Enabling advances in diagnosis, patient stratification and treatment for dilated cardiomyopathy patients and families.The DCM-NEXT consortium aims to enhance genetic testing and develop novel therapies for dilated cardiomyopathy by leveraging extensive clinical and omics data from 11,750 patients. | EIC Pathfinder | € 4.137.668 | 2023 | Details |
Engineering a living human Mini-heart and a swimming Bio-robotThe project aims to develop advanced in vitro human cardiac models, including a vascularized mini-heart and a bio-robot, to better assess cardiotoxicity and improve understanding of cardiovascular disease. | EIC Pathfinder | € 4.475.946 | 2022 | Details |
Cardiogenomics meets Artificial Intelligence: a step forward in arrhythmogenic cardiomyopathy diagnosis and treatment
The project aims to integrate genomics, proteomics, and structural analyses to clarify genotype-phenotype relationships in arrhythmogenic cardiomyopathy, paving the way for novel therapies.
Comprehensive Analysis of RBM20-induced Dilated Cardiomyopathies using Omics Approaches and Repair Interventions
CARDIOREPAIR aims to identify and therapeutically target RBM20 mutations in dilated cardiomyopathy using high-throughput genomics and bioengineering to improve heart health outcomes.
Enabling advances in diagnosis, patient stratification and treatment for dilated cardiomyopathy patients and families.
The DCM-NEXT consortium aims to enhance genetic testing and develop novel therapies for dilated cardiomyopathy by leveraging extensive clinical and omics data from 11,750 patients.
Engineering a living human Mini-heart and a swimming Bio-robot
The project aims to develop advanced in vitro human cardiac models, including a vascularized mini-heart and a bio-robot, to better assess cardiotoxicity and improve understanding of cardiovascular disease.